The recent years have seen a significant shift in the expectations for the therapeutic management of disseminated melanoma. The clinical success of BRAF targeted therapy suggests that long-term disease control may one day be a reality for genetically defined subgroups of melanoma patients. Despite this progress, few advances have been made in developing targeted therapeutic strategies for the 50% of patients whose melanomas are BRAF wild-type. The most well-characterized subgroup of BRAF wild-type tumors is the 15-20% of all melanomas that harbor activating NRAS (Neuroblastoma Rat Sarcoma Virus) mutations. Emerging preclinical and clinical evidence suggests that NRAS mutant melanomas have patterns of signal transduction and biological behavior that is distinct from BRAF mutant melanomas. This overview will discuss the unique clinical and prognostic behavior of NRAS mutant melanoma and will summarize the emerging data on how NRAS-driven signaling networks can be translated into novel therapeutic strategies.
INTRODUCTION
For many years, the prognosis for patients with disseminated melanoma has been poor. Responses to standard chemotherapy have been historically low and associated with median survival times of 6-10 months. 1 Although immunotherapy with interleukin-2 and ipilimumab provides durable responses in approximately 10% of metastatic melanoma patients, there are no established biomarkers to select patients and serious toxicities are common. 2 The recent years have seen significant shifts in our understanding of the drivers of malignant transformation. Cancer is now known to be a genetic disease, with defined tumor histologies often being uniquely dependent on (or 'addicted' to) the signaling activity of a restricted number of oncogenes. This knowledge, and the ability to target 'druggable' oncogenes using small-molecule inhibitors, has led to significant therapeutic breakthroughs in a number of cancers, including the targeting of the Bcr-Abl fusion protein in chronic myeloid leukemia, the ALK-EML4 fusion and mutant EGFR in non-small-cell lung cancer and c-KIT in gastrointestinal stromal tumors. [3] [4] [5] A major turning point in our understanding of melanoma biology was the 2002 discovery that the majority (450%) of all cutaneous melanomas harbored activating mutations in the serine/threonine kinase BRAF. 6 The identification of mutant BRAF as a bona fide oncogene in melanoma led to the rapid development of small-molecule BRAF inhibitors (such as vemurafenib and dabrafenib), which were subsequently shown to increase the overall survival of patients with metastatic BRAF mutant melanoma. [6] [7] [8] Following the Food and Drug Administration approval of vemurafenib in August of 2011 for patients with position 600 mutations in BRAF, attention has now turned to the 50% of melanoma patients whose tumors are BRAF wild-type, with the hope of making similar therapeutic breakthroughs. Among the cutaneous melanomas that lack BRAF mutations, 15-20% harbor mutations in the small GTPase NRAS (Neuroblastoma Rat Sarcoma Virus). 9 At present, little progress has been made in developing targeted therapy strategies for NRAS mutant melanoma. In this review, we will discuss the biological and signaling characteristics that are unique to NRAS mutant melanomas and will also outline the possible future strategies for their therapeutic management.
RAS PROTEINS
Ras genes were first identified as encoding for the proteins that mediated the transforming activity of Rat sarcoma viruses. It is now known that three Ras family members, NRAS, HRAS (Harvey Rat Sarcoma Virus) and KRAS (Kirsten Rat sarcoma virus), are often mutated in human cancers, and that 420% of all tumors harbor activating mutations in one of their RAS genes. 10 Ras proteins constitute a major family of low-molecular-weight plasma membrane-associated GTP-binding proteins. Within this superfamily (which also includes Rab, Rho and Arf), the Ras proteins primarily regulate growth, and function as molecular switches that link signals from receptor tyrosine kinases (RTKs) at the cell surface to transcription factors and cell cycle proteins in the nucleus. 11, 12 Under physiological conditions, Ras proteins exist in either an active (GTP-bound) state or an inactive (GDP-bound) state. The exchange of GDP for GTP, and the switching of Ras to its activated state is catalyzed by a family of guanine nucleotide exchange factors (GEFs), such SOS1, SOS2 and RASGRF GRB2. Signals from the activated RTK are relayed to Ras by the binding of Grb2 to the RTK at its SH2 domain. This then recruits SOS to the plasma membrane through binding of two SH3 domains, and SOS in turn catalyzes the GDP to GTP exchange on Ras 14 ( Figure 1 ). Once activated, Ras recruits and stimulates a number of intracellular signaling pathways, including the Raf/ MEK/ERK mitogen-activated protein kinase (MAPK) pathway, the phosphoinositide 3-kinase (PI3K)/AKT pathway, the Ral guanine nucleotide exchange factors such as Ral-GDS and phospholipase Ce (Figure 2 ). 15 MUTANT RAS AS AN INITIATING MELANOMA ONCOGENE Despite much attention being focused upon BRAF mutant melanoma, NRAS was actually the first melanoma oncogene to be identified. In 1984, a screen of melanoma cell lines for genes that possessed transforming properties identified activating mutations in NRAS in 4/30 samples. 16 In a further observation, it was noted that mutant Ras expression was heterogeneous within metastatic lesions derived from the same patient (found only in 1/5 samples). 16 Currently, mutations in NRAS, KRAS and HRAS are known to be present in 20%, 2% and 1% of all melanomas, respectively. 17 With regards to NRAS, the most common oncogenic change (480% of all NRAS mutations) reported is a point mutation leading to the substitution of glutamine to leucine at position 61, with mutations at positions 12 and 13 occurring less frequently. 9 Position 61 mutations also account for the majority of HRAS mutations in melanoma, whereas most KRAS mutations are at position 12 (http://www.sanger.ac.uk/genetics/ CGP/cosmic/). From a mechanistic standpoint, Ras mutations at position 61 are associated with impaired GTPase activity and the locking of the Ras protein into its activated (GTP-associated) conformation. Mutations at positions 12 and 13 render Ras insensitive to the physiological mechanisms of inactivation by the Ras GTPase-activating proteins. 9 Once mutated, Ras drives cellular transformation through a network of signal-transduction pathways involved in growth, motility and survival ( Figure 2 ). Although it is not clear why NRAS mutations are more frequent in melanoma compared with HRAS or KRAS mutations, there is some suggestion that NRAS may be overexpressed in melanocytes relative to other Ras isoforms. It is also possible that NRAS may activate different signaling pathways to KRAS and HRAS, an idea supported by the observation that NRAS has greater transforming activity than KRAS in experimental models of melanoma. 18 The available evidence suggests that Ras mutations are acquired at an early stage in the oncogenic process. Benign common nevi most commonly (480%) harbor mutations in BRAF, with NRAS mutation being less frequent (B14%). 19 In contrast, congenital nevi (for example, those that develop in utero, independently of ultraviolet exposure) do not possess BRAF mutations and instead frequently (81%) harbor NRAS mutations. 20 Spitz nevi, large benign melanocytic lesions that are histologically indistinguishable from melanoma, often (B11% of cases) exhibit concurrent amplification and mutation in HRAS, in the absence of significant proliferative capacity. 21 Taken together, these data suggest that although Ras mutations are found in melanoma precursor lesions, these do not appear to initiate oncogenic transformation in isolation and require other cooperating genetic events. These ideas are supported by the observation that most nevi rarely progress to melanoma and typically exhibit signs of replicative senescence. 22, 23 Genetically engineered mouse models of melanoma driven through mutant HRAS or NRAS have suggested a role for concurrent loss or inactivation of the tumor suppressor p16
INK4A , deletion of p53 or exposure to ultraviolet light. 24, 25 These studies are supported by the finding that NRAS mutant, but not BRAF mutant, melanoma is frequently associated with methylation of the p16 INK4A promoter. 26 Sox10, a transcription factor implicated in pigment cell development and differentiation, has also recently been shown to be essential for the maintenance of both NRAS mutant melanomas and giant congenital nevi. 27 Silencing of Sox10, either through haploinsufficiency or short hairpin RNAmediated knockdown, was found to revert melanoma formation in vivo through effects upon proliferation, survival and the suppression of neural crest stem cell properties. 27 Cell culture studies have confirmed the role of NRAS mutations in the growth of melanoma cell lines, with the small interfering RNA (siRNA)-mediated knockdown of NRAS found to inhibit growth associated with decreased expression of cyclins D1 and E2. 28 At the same time, it was noted that siRNA knockdown of NRAS reversed invasive capacity, an effect associated with the decreased expression of the cytoskeletal proteins paxillin, leupaxin and vinculin. 28 One other subgroup of melanomas (accounting for o1% of all melanomas) with Ras dependence is those with 'low-activity' BRAF mutations, such as those found at positions 466, 464 and 597. 29 (Note: although these were originally reported as positions 465, 463 and 596, they were later renumbered to correct an earlier sequencing error). Cell lines with low-activity BRAF mutations show an impaired activation of MAPK signaling in isolated kinase assays and often harbor concurrent NRAS mutations at positions 12 and 13. 30 Unlike melanoma cell lines with BRAF V600E/D mutations, low-activity mutant BRAF cell lines are sensitive to the growth-inhibitory effects of Ras-neutralizing antibodies as well as cell death induced by the CRAF/multikinase inhibitor sorafenib. 29, 31 It is therefore likely that strategies designed to target Ras mutant melanoma could also be effective in low-activity BRAF mutant melanoma. 
CLINICAL AND PROGNOSTIC SIGNIFICANCE OF NRAS MUTATIONS IN MELANOMA
It is now accepted that melanoma is a diverse collection of melanocytic neoplasms whose biological behavior can be defined by their pattern of oncogenic mutations. 32, 33 A recent histopathological analysis of a large series of melanoma specimens, grouped according to their BRAF/NRAS mutational status, showed BRAFmutated melanomas to possess morphological features that were distinct from tumors that were BRAF wild-type. 32 It was found that BRAF-mutated melanomas had an increased tendency to upward migration and nest formation and gave rise to larger, rounded, more pigmented tumor cells. In contrast, NRAS-mutated melanomas were not found to exhibit these morphological and phenotypic characteristics. 32 The presence of an NRAS mutation in the melanoma is also of prognostic significance. The typical patient with NRAS mutant melanoma tends to be older (455 years of age) with a more chronic pattern of ultraviolet exposure than a patient with a BRAF mutant melanoma. 34, 35 Overall, patients with NRAS mutant melanomas have been found to have thicker tumors at presentation. These tumors are typically located at the extremities and have greater rates of mitosis than BRAF mutant melanomas. 34, 36 Despite NRAS mutant melanomas having lower rates of ulceration than BRAF mutant melanoma, overall survival for NRAS mutant melanoma patients is worse than their wild-type counterparts. [34] [35] [36] INTRACELLULAR SIGNALING IN NRAS MUTANT MELANOMA Although NRAS and BRAF mutant melanomas share a set of common signaling pathways, significant differences exist in how these are regulated. In normal human melanocytes, MAPK activation occurs following stimulation with growth factors such as stem cell factor, fibroblast growth factor and hepatocyte growth factor 37 ( Figure 3 ). Under these normal physiological conditions, stimulation of the pathway occurs following the Rasmediated activation of Raf. 38 MAPK signaling in melanocytes proceeds through BRAF rather than CRAF (also called Raf-1), with Raf-isoform selectivity being determined through the concurrent growth factor-mediated activation of adenylate cyclase 38, 39 ( Figure 3 ). Increased adenylate cyclase activity leads to the accumulation of cyclic AMP and the activation of protein kinase A (PKA). This then inactivates CRAF via its direct phosphorylation at two inhibitory sites (S43 and S233) 40, 41 ( Figure 3 ). The high frequency of BRAF mutations found in melanoma likely stems from the lineage-specific reliance of melanocytes upon BRAF signaling for their growth factor-mediated MAPK activation.
Interestingly, BRAF is not required for MAPK activation in every melanoma, with NRAS mutant melanomas being instead reliant upon CRAF signaling 38 ( Figure 3 ). CRAF-mediated MAPK signaling in NRAS mutant melanoma cells is dependent on two parallel mechanisms: the inactivation of BRAF (permitting Raf isoform switching) and deregulation of PKA signaling (that prevents CRAF inactivation). 38 The inactivation of BRAF is achieved through a negative feedback mechanism in which ERK limits RAF signaling by phosphorylating it at S151, T401, S750 and T753 42 ( Figure 3 ). The S151 site in BRAF is close to the Ras-binding domain, and its phosphorylation appears to prevent the Ras/BRAF interaction. 39 Phosphorylation of BRAF at T401, S750 and T753 disrupts the dimerization of BRAF with CRAF. 42 The deregulation of PKA signaling occurs as a result of increased expression of the cyclic AMP degrading enzyme phosphodiesterase IV that limits PKA activity and in turn prevents CRAF from being phosphorylated at its inhibitory sites 39 ( Figure 3 ). The potential therapeutic implications of these findings were demonstrated by the ability of selective phosphodiesterase IV inhibitors to prevent the growth and increase apoptosis in NRAS mutant melanoma cell lines. 39 Constitutive MAPK activity is known to be essential for melanoma initiation and progression. 43 Signals through this pathway are responsible for the uncontrolled growth that characterizes melanoma, and occur via regulation of the G1 checkpoint through the increased expression of cyclin D1 and downregulation of the cell cycle inhibitor p27 KIP1 . 44, 45 MAPK signaling also has a critical role in melanoma survival through the phosphorylation (at S69) and proteasomal degradation of the proapoptotic protein BIM and via p90RSK-mediated effects upon BAD. 46, 47 In addition to the well-known role of MAPK signaling in melanomagenesis, in vitro and animal modeling studies have suggested that the PI3K/AKT cascade also has a critical role in melanoma development. 48, 49 Once activated at the plasma membrane, PI3K phosphorylates phosphotidylinositol-4,5, biphosphate(PIP2) to PIP3, which in turn activates the downstream kinases PDK1 and AKT. Once active, AKT promotes melanoma cell survival through direct phosphorylation of BAD and through the negative regulation of BIM expression via the phosphorylation and inactivation of FOXO3a.
46,50-52 Signals through the PI3K/AKT pathway are also critical for cell cycle entry, and regulate the G1 cell cycle checkpoint by phosphorylating and inactivating glycogen-3 synthase kinase (GSK3)b, leading to the modulation of cyclin D1.
53 PI3K/AKT signaling also has important downstream effects upon protein turnover and cell glucose metabolism via the regulation of the mTOR/S6K and GSK3b signaling pathways. 54 Like the MAPK pathway, PI3K/AKT signaling is differentially regulated between NRAS and BRAF mutant melanoma, with NRAS mutant melanomas rarely harboring either mutations in, or silencing of the negative regulator of the PI3K pathway, phosphatase and tensin homolog (PTEN). 55, 56 In addition, activating mutations in AKT3, which are sometimes found in BRAF mutant melanoma, have not been observed in NRAS mutant melanomas. 57 Despite data implying that mutant NRAS should activate MAPK and PI3K/AKT signaling concurrently, a recent analysis of clinical melanoma specimens and cell lines showed NRAS mutant melanomas to exhibit lower levels of constitutive AKT signaling than those with BRAF mutations. 56 The significance of this observation is still under investigation.
Another family of less well-characterized mediators of mutant NRAS are the Ral guanine nucleotide exchange factors such as Ral-GDS, RGL1 and RGL2. 15 Ral signaling is known to have a role in cell growth through transcriptional activation of cyclin D1, and (in concert with AKT) in cell survival, through the regulation of BIM and FasL expression. 15, 58 Increased Ral activity has also been implicated in cytoskeletal reorganization, associated with increased filopodia formation. 58 Although there is little evidence of melanomas harboring Ral-GDS mutations, Ral activity appears to be required for the development of NRAS mutant melanoma. [59] [60] [61] In animal xenograft models, short hairpin RNA knockdown of RalA was noted to delay the growth of human NRAS mutant melanoma cell lines. 60 A recent analysis of the role of Raf, PI3K and Ral signaling in immortalized melanocytes revealed distinct requirements for each pathway in oncogenic transformation. 61 Specifically, it was shown that whereas Raf and PI3K were important for overcoming oncogene-induced senescence and invasion, signaling through Ral was a prerequisite for anchorageindependent growth. 61 The requirement for multiple signaling pathways in the development of NRAS mutant melanoma development was demonstrated by the fact that no one individual signaling pathway fully recapitulated the transforming activity of oncogenic Ras.
61
Rac1 is a small GTPase that has been implicated in cell cycle regulation and Ras-mediated transformation in vitro as well as KRAS-driven lung cancer formation in vivo. 62, 63 Recent studies have shown Rac1 to be a critical mediator of NRAS Q61K signaling in melanocytes, with depletion of Rac1 being found to impair melanocyte survival in vivo. 64 A potential role of Rac1 signaling in the progression of NRAS mutant melanoma was also demonstrated, with the pharmacological or genetic inhibition of Rac1 being found to decrease invasion, growth and the lymph node metastasis of mouse melanocytes transformed by NRAS Q61K. 64 In this instance, depletion of Rac1 was associated with decreased signaling through both the PI3K/AKT and MEK/ERK signaling pathways. 64 
THERAPEUTIC STRATEGIES FOR NRAS MUTANT MELANOMA
Farnesyl transferase inhibitors NRAS has so far proven to be intractable to conventional drug discovery. The main 'Ras-directed' therapies to be investigated thus far have been the farnesyl transferase inhibitors, a class of drugs designed to prevent the post-translational modification of Ras and its insertion into the plasma membrane. 65 Although this strategy showed some preclinical promise, the clinical experience has been disappointing with serious off-target effects reported and few responses observed, even in tumors with high rates of Ras mutations (such as colorectal carcinoma). [65] [66] [67] The lack of success with farnesyl transferase inhibitors is attributable to the fact that many critical cellular proteins are farnesylated in addition to Ras and the fact that alternative post-translational modifications exist that allow for membrane targeting of Ras in the absence of FT activity. In melanoma, a small phase II trial of farnesyl transferase inhibitors in genetically unselected patients showed very little clinical activity. Other attempts to target directly Ras have involved the downregulation of Ras protein expression using either antisense oligonucleotides or siRNAs. Despite preclinical evidence that Ras knockdown can be achieved using siRNA, the approach has proven technically challenging in the clinical setting. 28 Current approaches are now centered upon improved methods of siRNA delivery in vivo, using nanoparticle-based delivery systems. 68 
MEK inhibitors
Given the lack of success thus far in directly targeting NRAS, focus has instead shifted to targeting the critical signal-transduction pathways that drive Ras-mediated transformation. Of these, targeting the MAPK pathway, using allosteric MEK inhibitors, has received the most attention. In preclinical studies, melanoma cell lines with oncogenic NRAS showed variable response to MEK inhibitors, with some cell lines exhibiting high sensitivity and some demonstrating near-total resistance. 44, 69 A recent highthroughput genomic analysis, correlating cell line mutational status with drug response (the cancer cell line 'encyclopedia'), demonstrated a link between the sensitivity of NRAS mutant melanoma cell lines to MEK inhibition and elevated expression of the aryl hydrocarbon receptor. 70 The dependence of NRAS mutant melanoma cell lines upon aryl hydrocarbon receptor signaling was confirmed through short hairpin RNA knockdown, and it was noted that MEK inhibition in these cell lines was associated with inhibition of aryl hydrocarbon receptor signaling function. 70 Although MEK inhibitors, such as CI-1040 and AZD6244, have been investigated in melanoma patients, most of the studies were performed before the era of routine genetic testing. In most of the published trials to date, patients were unselected and significant intratumoral phospho-ERK inhibition was not observed at the maximum-tolerated doses. 71 There were some notable exceptions with one NRAS mutant melanoma patient remaining on AZD6244 therapy for three cycles, associated with 470% tumor shrinkage and near-total inhibition of intratumoral phospho-ERK. 71 Overall, the results of clinical trials with early-generation MEK inhibitors were disappointing (B10% objective response rate) and retrospective genotyping for the NRAS/BRAF mutations did predict for clinical benefit.
Enthusiasm for targeting MEK in NRAS mutant melanoma patients has received new attention with the clinical development of the third-generation MEK inhibitors trametinib (GSK1120212) and MEK162 (ARRY-438162). Both trametinib and MEK162 are potent inhibitors of MEK1/2 with sustained MAPK pathway inhibition at clinically achievable doses. 72, 73 Trametinib has now demonstrated strong activity in BRAF mutant melanoma patients treated in the phase III METRIC study. 74 The overall response rate with trametinib was 24%, with a median progression-free survival (PFS) of 4.8 months, both significantly better than standard chemotherapy. Similarly, MEK162 has shown promising clinical activity (overall response rate was 23%) in BRAF mutant melanoma patients in a recent phase II study. 75 Although these response rates are lower than the reported data for first-line treatment with the BRAF inhibitors vemurafenib and dabrafenib, it is important to note that patients in both of the MEK inhibitor studies had received multiple prior therapies and perhaps had more aggressive disease biology.
The first prospective clinical data on NRAS mutant melanoma patients treated with targeted therapy was recently presented. 75 As part of a combined study of BRAF and NRAS mutant melanoma patients, 30 metastatic melanoma patients whose tumors harbored an NRAS mutation were enrolled and treated with MEK162. The overall response rate was 21% and the median PFS was 3.6 months. Further study in this patient population will be necessary to confirm its clinical activity in comparison to other standard therapies. Although prospective data with trametinib in NRAS mutant melanoma patients is not available, early retrospective data from ongoing clinical studies suggest that trametinib may have activity in a subset of NRAS mutant melanoma patients. 76 Combination therapy with MEK and PI3K pathway inhibitors The evolving lesson of using small-molecule BRAF inhibitors in patients with BRAF V600E mutant melanoma suggest that resistance will always limit responses to single-agent therapy and that multidrug combinations are necessary. 8, [77] [78] [79] [80] There is already good evidence from animal models of Ras-driven cancers that the simultaneous inhibition of MEK þ PI3K leads to greater extent of tumor regression than either inhibitor alone. 81 From a mechanistic standpoint, the MEK and PI3K/AKT pathways seem to converge at the level of cell survival, through the co-regulation of the proapoptotic protein BAD, as well as the level of capdependent protein translation, through the translational repressor 4E-BP1. 82, 83 Similar findings have also been reported in xenograft studies of NRAS mutant human melanoma cell lines, with short hairpin RNA knockdown of BRAF þ CRAF or BRAF þ PI3K expression being found to delay and inhibit tumor formation. 84 In melanoma cell lines where BRAF inhibitor resistance is mediated through an acquired NRAS mutation, the combination of an MEK inhibitor (trametinib) with a PI3K/mTOR inhibitor (GSK2126458) was noted to overcome drug resistance and inhibit cell survival. 79 It is not yet clear what the optimal combination of signaltransduction inhibitors will be for NRAS mutant melanoma and even whether any one combination will be effective for all melanomas with oncogenic NRAS. Presently, there are 14 active or recently completed phase I clinical trials investigating the combination of PI3K pathway and MEK inhibitors (Table 1) . Data presented on the dose escalation of the phase I study of the PI3K inhibitor BKM120 and trametinib was promising for tolerability and potential efficacy. 85 A total of 66 patients were treated at increasing doses of both drugs, reaching the maximum-tolerated doses of 70 mg daily for BKM120 and 1.5 mg daily for trametinib. Of note, the dose of trametinib in phase III study of BRAF mutant patients (METRIC study) was 2 mg daily. 74 Enrollment focused on RAF and RAS mutant tumors, with 10 melanoma patients treated in total. While the strongest clinical activity was seen in KRAS mutant ovarian carcinoma patients (three partial responses by the RECIST (Response Evaluation Criteria In Solid Tumors) criteria), there was tumor regression that did not meet the RECIST criteria seen in three melanoma patients. Completed data on this study and others are eagerly awaited.
Feedback inhibition and RTK signaling
The experience of targeted therapy in many cancer types has demonstrated that resistance can often occur through the derepression of feedback inhibition and compensatory upregulation of signaling through parallel pathways. 86 Understanding and developing strategies that limit these complex adaptive signaling responses are likely to prove critical in the use of targeted therapy regimens for the long-term management of disease. The scale of this problem was recently indicated by an integrated genomic/ proteomic study of triple-negative breast cancer in which MEK inhibition led to the rapid remodeling of the RTK kinome associated with increased expression of multiple RTKs. 87 Mechanistically, it was observed that the short-term inhibition of MAPK signaling decreased the expression of c-Myc, which in turn initiated autocrine signaling through HER2, RON, Axl, VEGFR and PDGFRb. 87 The drug-induced increase in RTK signaling allowed the cells to escape from MEK inhibitor therapy and could be reversed through the combination of an MEK inhibitor with the pan-RTK inhibitor sorafenib. 87 Compensatory signaling of a similar nature was also observed following the siRNA knockdown of RAS, with recent studies showing that inhibition of KRAS in colorectal carcinoma led to a rebound increase in PI3K signaling. 88 Mechanistically, this appeared to result from a suppression of MEK-mediated TORC1 activity leading to derepression of IRS-1 and increased AKT signaling mediated through insulin-like growth factor 1 receptor (IGF-1R). 88 Although not yet studied in the context of NRAS mutant melanoma, functional IGF-1R autocrine signaling loops are known to be present in both melanoma cell lines and tumor specimens, raising the possibility that these may contribute to the escape from MEK inhibitor therapy. 89 A possible role for rebound IGF-1R signaling in the de novo resistance of a subset of BRAF mutant melanoma cells to MEK inhibition has already been demonstrated. 90 In this instance, MEK inhibitor sensitivity was restored through combination with either a TORC1/2 inhibitor or an IGF-1R inhibitor. 90 In addition to IGF-1R, comprehensive phospho-proteomic screening of melanoma cell lines revealed a diverse array of RTKs to be expressed, including TYRO3, Axl, MERTK, EPHB2, MET, IGFR1, EGFR, KIT, HER3 and HER4. 89, 91 The potential role of these RTKs in NRAS mutant melanoma, and their involvement in adaptive signaling responses following kinase inhibition, remains to be determined. Of the RTKs expressed in melanoma, the TAM family (Tyro3, Axl, MER) receptor kinase Axl was noted to be over-represented in NRAS mutant melanoma. 91, 92 In the majority of NRAS mutant cell lines examined, Axl was activated through a Gas6-driven autocrine loop and was linked to the activation of AKT signaling. 92 Functional studies indicated that Axl signaling was required for the invasive behavior of NRAS mutant melanoma cell lines. 92 Although inhibition of the PI3K pathway downstream of RTK signaling may be one approach to disrupt cellular adaptation to RAF and MEK inhibition, preclinical and early clinical data are promising for direct inhibition of RTKs and other tyrosine kinases. Recent preclinical work with RAF-265, an inhibitor of BRAF, CRAF, VEGFR2, PDGFR and c-Kit, has shown induction of tumor regression in BRAF wild-type melanoma xenografts, including one specimen with a Q61 mutation in NRAS.
93 RAF-265 is now being studied in combination with MEK162 in patients with BRAF or RAS mutant tumors, including NRAS mutant melanoma (NCT01352273). A similar concept is being explored with the combination of pazopanib (VEGFR, PDGFR, c-Kit and fibroblast growth factor receptor inhibitor) with trametinib in a phase I study (NCT01438554).
Recent data on broad tyrosine kinase inhibition has also been presented in metastatic melanoma patients treated with the combination of ARQ 197, a specific c-Met inhibitor, and sorafenib, an inhibitor of VEGFR, PDGFR, c-Kit and RAF. 94 In this doseescalation study, a total of 16 melanoma patients were treated at the recommended phase II dose level. The overall response rate was 25%, with a median PFS of 5.3 months. Interestingly, half of the patients in this cohort had NRAS mutant melanoma. Efficacy data showed one complete response and one partial response in this subgroup, along with an overall median PFS of 9.2 months. These findings suggest that tyrosine kinase inhibition may prove Clinical and prognostic behavior of NRAS mutant melanoma IV Fedorenko et al to be valuable therapeutic strategy in NRAS mutant melanoma and further study is warranted.
NRAS MUTATIONS AS A MECHANISM OF THERAPEUTIC ESCAPE FROM BRAF INHIBITOR THERAPY: MUTATIONAL HETEROGENEITY IN MELANOMA?
Despite the increases in both PFS and overall survival seen in BRAF mutant melanoma patients receiving vemurafenib therapy, resistance occurred in nearly every case. 8, 77 In a number of instances, therapeutic escape was associated with the acquisition of position 61 mutations in NRAS that seemed to be lacking in the original tumor. 95 This phenomenon was also reported in cell culture studies, with the emergence of RAS mutations being noted in BRAF mutant melanoma cell lines following chronic vemurafenib/dabrafenib treatment. 79, 96, 97 Insights into the potential mechanism underlying this apparent mutational switch came from a recent study into the role of acquired KRAS mutations in the resistance of colorectal carcinoma to EGFR inhibition. 98 Using clinical specimens and mathematical modeling, it was demonstrated that low levels of mutant KRAS pre-existed within ostensibly KRAS wild-type tumors, and that EGFR blockade led to the expansion of these subclones. 98 Although BRAF and NRAS mutations are mutually exclusive at the single melanoma cell level, there is evidence that a minor fraction of patients have melanomas containing coexistent clones with different oncogenic mutations. At least two independent studies have reported the presence of BRAF mutant and NRAS mutant cells within the same melanoma specimen. 99, 100 If confirmed in a larger patient cohort, the issue of mutational polyclonality could have important clinical implications, particularly in light of the overwhelming pre-clinical evidence that BRAF inhibitors confers a growth and survival advantage to NRAS mutant melanoma cells. [101] [102] [103] The paradoxical activation of MAPK signaling observed in Ras mutant cells following BRAF inhibitor treatment occurs following the increased formation of Raf dimers consisting of either CRAF homodimer pairs or dimers between drug-bound BRAF and CRAF 103, 104 ( Figure 4 ). Once formed, the dimers activate downstream MEK signaling. The requirement for dimer formation in the paradoxical activation of MAPK signaling was confirmed by the lack of MAPK activation seen in BRAF inhibitor treated Ras mutant cell lines transfected with dimerization-deficient isoforms of Raf. 103, 105 Other studies have provided evidence that the BRAFinhibitor-mediated paradoxical MAPK activation also proceeds via upstream Ras signaling through a mechanism involving the disruption KRAS and NRAS nanoclustering at the cell membrane. 106 Intriguingly, it was noted that although Ras nanoclustering promoted Raf signaling, this unexpectedly led to an inhibition of AKT signaling. 106 From a clinical standpoint, the ability of BRAF inhibitors to stimulate paradoxically the growth of Ras mutant cells underlies the emergence of HRAS mutant squamous cell carcinomas, commonly seen in patients on vemurafenib/trametinib therapy. 107, 108 There is evidence that BRAF inhibitor therapy may also lead to the development of new, BRAF wild-type primary melanomas (of which 1/12 was noted to be NRAS mutant). 109 Taken together, these findings underscore the need for the future development of highly sensitive BRAF/NRAS mutational testing protocols that gives a systemic readout of mutational status before the initiation of BRAF inhibitor therapy.
NRAS mutations as a predictor of immune therapy response Despite the current lack of effective targeted therapies for NRAS mutant melanoma, there is some evidence that NRAS mutational status may predict for response to other therapies. A recent retrospective analysis of patients treated with high-dose interleukin-2 demonstrated that the majority of the responders were NRAS mutant and that patients with either BRAF mutant or BRAF/ NRAS wild-type melanoma were less likely to respond. 110 It is not yet clear whether BRAF or NRAS mutational status predicts for better responses in melanoma patients receiving the anti-CTLA-4 antibody ipilimumab or anti-PD-1 antibodies. In the only published analysis to date, the disease control rate of melanoma patients on ipilimumab therapy was noted to be 30% and 33% for those with and without BRAF mutations, respectively. 111 A further breakdown of the BRAF wild-type patients into those with NRAS mutations was not available.
FUTURE STRATEGIES
Although the current immunotherapeutic agents may offer some hope to NRAS mutant melanoma patients, these therapies are not mutation specific, are associated with modest response rates and carry the risk of significant toxicities. Many targeted strategies are now being evaluated for NRAS mutant melanoma, although these tumors appear to be more heterogeneous than those with BRAF mutations. It is therefore likely that multiple strategies may have to be developed for NRAS mutant melanoma in concert with more sophisticated mutational screening. So far, the most promising data from clinical investigations are with MEK inhibition. However, the relatively short PFS indicates that either combination strategies or other targeted approaches will be necessary to achieve more clinically important disease responses. Further prospective biomarker-driven investigations will be crucial for PI3K pathway, RTK and other targeted therapeutic approaches. 
